Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, PhD, David N Saenz, Raffaella Soldi, Baohua Sun, MD PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Steven M. Kornblau, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Lucia Masarova, MD, Steve Horrigan, Joseph David Khoury, MD, Sunil Sharma, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 177.

https://doi.org/10.1182/blood-2018-177

Published: 2018

Journal Articles

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Warren Fiskus, BSc, PhD, Christopher Peter Mill, PhD BA, Raffaella Soldi, Roulan Han, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, David N Saenz, Courtney D. DiNardo, MD MSc, Gautam Borthakur, MD, Tapan M. Kadia, MD, Wendy Jin, Thurika Ganesh, Vaishnavi Rao, Joseph David Khoury, MD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 3930.

https://doi.org/10.1182/blood-2018-99-114198

Published: 2018

Journal Articles

Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells

Christopher Peter Mill, PhD BA, Tianyu Cai, PhD, Warren Fiskus, BSc,PhD, Gautam Borthakur, MD, Steven M. Kornblau, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Agnieszka J Nowak, Dyana T. Saenz, PhD, David N Saenz, Baohua Sun, MD PhD, Thurika Ganesh, Wendy Jin, Vaishnavi Rao, Joseph David Khoury, MD, Yu Shen, Marina Y. Konopleva, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2018-99-113976

Published: 2018

Journal Articles

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, BSc,PhD, Kanak Raina, PhD, Yimin Qian, PhD, Andrew Crew, Dyana T. Saenz, PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, David N Saenz, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1265.

https://doi.org/10.1182/blood.V130.Suppl_1.1265.1265

Published: 2017

Journal Articles

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, Yimin Qian, PhD, Kanak Raina, PhD, David N Saenz, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 1239.

https://doi.org/10.1182/blood.V130.Suppl_1.1239.1239

Published: 2017

Journal Articles

Targeted Therapy for AML Expressing RUNX1 Mutation

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Courtney D. DiNardo, MDMSc, Yimin Qian, PhD, Kanak Raina, PhD, Koichi Takahashi, MD, Tapan Kadia, MD, Dyana T. Saenz, PhD, Agnieszka J Nowak, Baohua Sun, MD PhD, Craig M Crews, PhD, Kapil N. Bhalla, MD

Blood (2017) 130 (Supplement 1): 2472.

https://doi.org/10.1182/blood.V130.Suppl_1.2472.2472

Published: 2017

Journal Articles

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Liang Zhang, MD PhD, Kanak Raina, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Dyana T Saenz, PhD, Christopher P Mill, PhD, Michael Wang, MD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 1058.

https://doi.org/10.1182/blood.V128.22.1058.1058

Published: 2016

Journal Articles

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T Saenz, PhD, Warren Fiskus, PhD, Kanak Raina, PhD, Taghi Manshouri, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Christopher P Mill, PhD, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 747.

https://doi.org/10.1182/blood.V128.22.747.747

Published: 2016

Journal Articles

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Dyana T Saenz, Warren Fiskus, PhD, Taghi Manshouri, PhD, Baohua Sun, MD PhD, Stephanie Krieger, Simrit Parmar, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 1269.

https://doi.org/10.1182/blood.V126.23.1269.1269

Published: 2015

Journal Articles

BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Dyana T Saenz, Stephanie Krieger, Liang Zhang, MD PhD, Simrit Parmar, MD, Michael Wang, MD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 3704.

https://doi.org/10.1182/blood.V126.23.3704.3704

Published: 2015

Journal Articles

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Santhana G. T. Devaraj, PhD, Warren Fiskus, PhD, Bhavin Shah, Sunil Sharma, Jun Qi, PhD, Baohua Sun, MD PhD, Saikat Saha, PhD, Swaminathan Padmanabhan Iyer, MD, Youli Zu, MD PhD, James Bradner, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 3534.

https://doi.org/10.1182/blood.V124.21.3534.3534

Published: 2014

Journal Articles

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Saikat Saha, PhD, Warren Fiskus, PhD, Sunil Sharma, Bhavin Shah, Anna T Rogojina, Santhana G. T. Devaraj, PhD, Baohua Sun, MD PhD, Christopher Leveque, MD, Youli Zu, MD PhD, Swaminathan Padmanabhan Iyer, MD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 618.

https://doi.org/10.1182/blood.V124.21.618.618

Published: 2014

Journal Articles

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Bhavin Shah, Jun Qi, PhD, Santhana G. T. Devaraj, PhD, Swaminathan Padmanabhan Iyer, MD, Sunil Sharma, James Bradner, MD, Youli Zu, MD PhD, Kapil N. Bhalla, MD

Blood (2014) 124 (21): 918.

https://doi.org/10.1182/blood.V124.21.918.918

Published: 2014

Journal Articles

Sox4 Is Essential for Initiation and Progression of Acute Lymphoblastic Leukemia Induced by P190-BCR-ABL Transformation

Haiqing Ma, MD, PhD, Saradhi Mallampati, PhD, Baohua Sun, MD, PhD, Yun Gong, MD, Véronique Lefebvre, Xiaoping Sun, MD, PhD

Blood (2011) 118 (21): 564.

https://doi.org/10.1182/blood.V118.21.564.564

Published: 2011

Journal Articles

Conditional Knockout of Sox4 Markedly Affects Early B Lymphopoiesis in Adult Mice

Baohua Sun, MD, PhD, Saradhi Mallampati, PhD, Yun Gong, MD, Donghai Wang, PhD, Véronique Lefebvre, Xiaoping Sun, MD, PhD

Blood (2011) 118 (21): 913.

https://doi.org/10.1182/blood.V118.21.913.913

Published: 2011

Journal Articles

Conditional Knockout of Sox4 Markedly Affects B Lymphopoiesis in Adult Mice.

Baohua Sun, MD, PhD, Saradhi Mallampati, PhD, Yun Gong, MD, Donghai Wang, PhD, M. James You, MD, PhD, Hesham M. Amin, MD, MSC, Yupo Ma, MD, PhD, Klaus Rajewsky, MD, Veronique Lefebvre, PhD, Xiaoping Sun, MD, PhD

Blood (2009) 114 (22): 2524.

https://doi.org/10.1182/blood.V114.22.2524.2524

Published: 2009

Journal Articles

Rooting into the Soil, a Model for the Role of Sox4 in Leukemia

Saradhi Mallampati, PhD, Baohua Sun, MD, PhD, Yun Gong, MD, Enze Wang, M. James You, MD, PhD, Hesham M. Amin, MD, MSC, Yupo Ma, MD, PhD, Haifa Shen, MD, PhD, Patrick Zweidler-McKay, MD, PhD, Dan Jones, MD, PhD, Cheng Yin, Armand Glassman, MD, Hagop M. Kantarjian, MD, Ralph B. Arlinghaus, PhD, Xiaoping Sun, MD, PhD

Blood (2008) 112 (11): 3794.

https://doi.org/10.1182/blood.V112.11.3794.3794

Published: 2008

Journal Articles

Protein Expression Profiling of Cytokines and Cytokine Receptors on Purified Chronic Lymphocytic Leukemia Cells.

Zhifeng Yu, PhD, Baohua Sun, MD, PhD, Hagop M. Kantarjian, MD, Hesham M. Amin, MD, Xiaoping Sun, MD, PhD

Blood (2007) 110 (11): 4709.

https://doi.org/10.1182/blood.V110.11.4709.4709

Published: 2007

NARROW

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Synergistic Pre-Clinical Activity of Targeted Inhibition of KDM1A and BET Proteins Against Human AML Blast Progenitor Cells

Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells

Preclinical Activity of Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) and Their Combination with Venetoclax or CDK4/6 Inhibitor Against Human Mantle Cell Lymphoma (MCL) Cells

Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Targeted Therapy for AML Expressing RUNX1 Mutation

Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells

Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells

Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD)

Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells

Sox4 Is Essential for Initiation and Progression of Acute Lymphoblastic Leukemia Induced by P190-BCR-ABL Transformation

Conditional Knockout of Sox4 Markedly Affects Early B Lymphopoiesis in Adult Mice

Conditional Knockout of Sox4 Markedly Affects B Lymphopoiesis in Adult Mice.

Rooting into the Soil, a Model for the Role of Sox4 in Leukemia

Protein Expression Profiling of Cytokines and Cytokine Receptors on Purified Chronic Lymphocytic Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only